MARKET

PHAT

PHAT

PHATHOM PHARMACEUTICALS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.09
-1.85
-4.88%
Opening 12:48 09/21 EDT
OPEN
37.03
PREV CLOSE
37.94
HIGH
37.18
LOW
35.69
VOLUME
14.74K
TURNOVER
--
52 WEEK HIGH
64.54
52 WEEK LOW
18.51
MARKET CAP
1.05B
P/E (TTM)
-4.3639
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference
FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate
GlobeNewswire · 09/09 13:30
Phathom Pharmaceuticals Reports Second Quarter 2020 Results
FLORHAM PARK, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financi
GlobeNewswire · 08/06 12:30
Todd Branning as Phathom Pharma CFO
Phathom Pharmaceuticals (PHAT +1.3%) appointed 25-year industry veteran Todd Branning as CFO, while interim CFO David Socks, will continue as a strategic a
seekingalpha · 07/13 20:04
Phathom Pharmaceuticals Appoints Todd Branning As Chief Financial Officer
Benzinga · 07/13 12:38
Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer
FLORHAM PARK, N.J., July 13, 2020 -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing.
GlobeNewswire · 07/13 12:30
Goldman Sachs Downgrades Phathom Pharmaceuticals to Sell, Announces $34 Price Target
Goldman Sachs analyst Paul Choi downgrades Phathom Pharmaceuticals (NASDAQ:PHAT) from Neutral to Sell and announces $34 price target.
Benzinga · 06/26 09:54
Microcaps mostly among midday movers
Seeking Alpha - Article · 06/15 16:31
Phathom Pharmaceuticals Provides Clinical Trial Status Update
GlobeNewswire · 06/15 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PHAT stock price target is 38.33 with a high estimate of 45.00 and a low estimate of 32.00.
EPS
Institutional Holdings
Institutions: 70
Institutional Holdings: 21.91M
% Owned: 75.63%
Shares Outstanding: 28.96M
TypeInstitutionsShares
Increased
21
1.32M
New
26
487.18K
Decreased
7
1.91M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.58%
Pharmaceuticals & Medical Research
-3.28%
Key Executives
Chairman/Independent Director/Co-Founder/Director
Tadataka Yamada
President/Chief Executive Officer/Director
Terrie Curran
Co-Founder/Chief Financial Officer/Primary Contact/Treasurer/Director
David Socks
Co-Founder/Chief Operating Officer
Azmi Nabulsi
Co-Founder
Aditya Kohli
Independent Director
Michael Cola
Independent Director
Heidi Kunz
Independent Director
Asit Parikh
Independent Director
Mark Stenhouse
Independent Director
James Topper
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average PHAT stock price target is 38.33 with a high estimate of 45.00 and a low estimate of 32.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PHAT
Phathom Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing treatments for gastrointestinal (GI) diseases. Its product candidate, vonoprazan, is an oral small molecule potassium competitive acid blocker (P-CAB). It is developing vonoprazan as an agent in the treatment of gastroesophageal reflux disease (GERD) and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. Vonoprazan accumulates in the secretory canaliculus where the proton pumps are present in their active state. Vonoprazan binds to proton pumps in both their inactive and active states and remains in the secretory canaliculus where it continues to inhibit acid secretion over an extended period.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Phathom Pharmaceuticals Inc stock information, including NASDAQ:PHAT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHAT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHAT stock methods without spending real money on the virtual paper trading platform.